Table 2.
The Distribution of the Questions and Answers Related to the Rational Use of Antibiotics
| Group 1 | Group 2 | p* value | |||||
|---|---|---|---|---|---|---|---|
| Question Number | Questions | Options | Number (n=225) | % | Number (n=230) | % | |
| 10 | The most important principle in rational antibiotic using? | Presence of infection that requires antibiotics use | 206 | 91.6 | 215 | 93.5 | 0.03 |
| General condition of the patient | 9 | 4.0 | 10 | 4.3 | |||
| Presence of immunosuppression | 9 | 4.0 | 1 | 0.4 | |||
| Recent infection history | 1 | 0.4 | 4 | 1.8 | |||
| 11 | Not having a rational antibiotics use purpose? | Common cold treatment | 207 | 92.0 | 198 | 86.1 | 0.006 |
| Simple cystitis treatment | 8 | 3.6 | 4 | 1.7 | |||
| Treatment of opportunistic infections | 8 | 3.6 | 22 | 9.6 | |||
| Treatment of invasive diarrhea | 2 | 0.8 | 6 | 2.6 | |||
| 12 | The most important purpose of empirical using? | Having a wide spectrum | 54 | 24.0 | 57 | 24.8 | 0.44 |
| Having a narrow spectrum | 2 | 0.9 | 7 | 3.0 | |||
| Covering the most probable infection factors | 165 | 73.3 | 162 | 70.4 | |||
| Including combined treatment as much as possible | 4 | 1.8 | 4 | 1.7 | |||
| 13 | The most important purpose of combined using? | The desire for keeping the infection under control as soon as possible | 91 | 40.4 | 104 | 45.2 | 0.59 |
| Reducing toxicity | 8 | 3.6 | 11 | 4.8 | |||
| Expanding the targeted active microorganism group | 100 | 44.4 | 93 | 40.4 | |||
| Bringing the active plasma concentration to the highest level | 26 | 11.6 | 22 | 9.6 | |||
| 14 | The most accurate definition of chemoprophylaxis purpose? | An optional process to prevent an infection with a high risk of progression | 153 | 68.3 | 120 | 52.2 | 0.003 |
| A routine process in an endemic area | 23 | 10.3 | 40 | 17.4 | |||
| A compulsory process in an endemic area | 29 | 12.9 | 35 | 15.2 | |||
| A protective process for diseases with high mortality risk | 20 | 8.5 | 35 | 15.2 | |||
| 15 | Not among the surgical prophylaxis purposes? | Preventing surgical site infections | 13 | 5.8 | 21 | 9.1 | 0.04 |
| Reducing postoperative infectious morbidity and mortality | 33 | 14.7 | 33 | 14.3 | |||
| Absolutely starting for all patients that undergo surgery | 96 | 42.7 | 85 | 37.0 | |||
| Avoiding negative changes in the patient/hospital microorganism flora | 83 | 36.8 | 91 | 39.6 | |||
| 16 | The thing you want to hear most from the representative of a drug company? | Emphasizing the efficacy and indications | 92 | 40.9 | 93 | 40.4 | 0.93 |
| Supporting the introduction with previously conducted scientific clinical studies | 90 | 40.0 | 88 | 38.3 | |||
| Emphasizing the ease of use, and the side effects and drug interactions | 40 | 17.8 | 45 | 19.6 | |||
| Supporting the presentation with medical and paramedical ingredients/promises | 3 | 1.3 | 4 | 1.7 | |||
Note: *Pearson’s chi-square test; the data are given as a number (percentage).